FierceBiotech

BioTime and the California Institute for Regenerative Medicine Sign Distribution Agreement for GMP-Compliant Stem Cell Lines

BioTime, Inc. and the California Institute for Regenerative Medicine Sign Distribution Agreement for GMP-Compliant Human Embryonic Stem Cell Lines ALAMEDA, Calif ...
Business Wire

Asterias Biotherapeutics, Inc., a Subsidiary of BioTime, Inc., Acquires Geron’s Embryonic Stem Cell Assets

MENLO PARK, Calif. & ALAMEDA, Calif.--(BUSINESS WIRE)--Asterias Biotherapeutics, Inc. and BioTime, Inc. (NYSE MKT: BTX) jointly announced today the closing of the transactions under the Asset ...
Pharmabiz

BioTime, CIRM sign agreement for GMP-compliant human Embryonic Stem cell lines

BioTime, Inc. announced an agreement with the California Institute for Regenerative Medicine (CIRM) to make five clinical-grade human Embryonic Stem (hES) cell lines available to California-based ...
FierceBiotech

BioTime Announces the Appointment of Jeffrey Janus as Vice President

BioTime, Inc.Peter GarciaChief Financial Officer510-521-3390, ext 367orJudith Segall510-521-3390, ext 301 BioTime, Inc. (NYSE MKT: BTX) today announced the appointment of Jeffrey Janus as its Vice ...
FiercePharma

BioTime Signs Exclusive Agreement with Jade Therapeutics for Ophthalmic Drug Delivery Applications of HyStem(R) Technology

BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced the signing of an exclusive sublicense agreement with ...
FiercePharma

BioTime Obtains Expanded License to HyStem® Technology

BioTime, Inc. (NYSE MKT: BTX) announced that the company has amended its license from the University of Utah to expand the field of use for which BioTime is licensed to produce and market products ...